Allergan (AGN) Dips as FDA Approves Sientra Silimed-Brand Implants
Tweet
Share
E-mailGet Alerts AGN Hot Sheet
Join SI Premium – FREE
Allergan, Inc. (NYSE: AGN) is ticking lower today following a release from competitor Sientra that it has received FDA approval of its portfolio of Silimed-brand silicone breast implants.
Shares are down 0.3 percent on the session Friday after being up as much as 0.8 percent on the session.
Shares are down 0.3 percent on the session Friday after being up as much as 0.8 percent on the session.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tenax shares Phase 3 LEVEL trial data at ESC Congress 2026
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
- NeOnc reports Phase 2a brain cancer trial results, plans FDA meeting
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
